SHPH · Shuttle Pharmaceuticals Holdings, Inc.
$3.52
+0.00 (+0.00%)
At close · Aug 25
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, the Company’s existing cash resources, the cash received from the equity offerings, and financing available under the revolving note are not expected to provide sufficient funds to carry out the Company’s operations through the next twelve months. The ability of the Company to continue as a going concern is dependent upon its ability to continue to successfully raise additional equity or debt financing to allow it to fund ongoing operations, fund milestone and contingent payments due under the APA, and commercialize and market the Molecule.ai platform in order to generate revenues. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$2.06M
Shares
585,129
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$11.72M
-28.2%
FY2025
Diluted EPS
-$71.60
+91.3%
FY2025
Operating Cash Flow
-$9.48M
-29.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | — | $100K | $100K | — | — | |
| $2.75M | $4.05M | $3.62M | $3.52M | $1.05M | $1.02M | |
| $6.24M | $5.67M | $1.39M | $1.05M | $473.71K | $36.5K | |
| — | $288.06K | — | — | — | — | |
| — | $290.11K | $5463 | — | — | — | |
| $11.18M | $11.92M | $7.7M | $5.89M | $2.34M | $1.74M | |
| — | $2.4M | $2.1M | $100K | — | — | |
| -$11.18M | -$11.92M | -$7.7M | -$5.89M | -$2.34M | -$1.74M | |
| — | $1090 | $38.14K | $79.12K | — | — | |
| $361.27K | $195.16K | -$1.45M | -$700.34K | -$2.65M | $590.86K | |
| — | — | — | -$6.59M | -$5M | -$1.15M | |
| -$10.82M | -$11.72M | -$9.14M | -$6.59M | -$5M | -$1.15M | |
| — | — | — | -$6.59M | -$6.75M | -$1.26M | |
| USD/shares | — | -$71.60 | -$796.50 | -$882.50 | -$1,260.00 | -$240.00 |
| USD/shares | — | -$71.60 | -$826.00 | -$882.50 | -$1,260.00 | — |
| shares | — | 163.79K | 11.48K | 7465.1 | 5350.968 | 4650.875 |
| shares | — | 163.79K | 11.55K | 7465.1 | 5350.968 | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.85×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 21 similar-size Drug Manufacturers - Specialty & Generic companies (of 102 listed).